Although we cannot infer causality from this analysis, the average treatment effect revealed that patients with IDH mutations in AML displayed significantly reduced LVEF during AML therapy after achieving a balanced distribution of baseline characteristics between the IDH1/2wildtype and IDH1/2mutated groups based on inverse probability of treatment weighting. This evidence concerns the gene IDH1 and acute myeloid leukemia.